WallStSmart

Merck & Company Inc (MRK)vsNational HealthCare Corporation (NHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 4170% more annual revenue ($66.57B vs $1.56B). NHC leads profitability with a 9.0% profit margin vs 4.8%. NHC appears more attractively valued with a PEG of 0.82. NHC earns a higher WallStSmart Score of 61/100 (C+).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

NHC

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 6.0Value: 5.3Quality: 9.0
Piotroski: 5/9Altman Z: 3.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued
NHCSignificantly Overvalued (-65.7%)

Margin of Safety

-65.7%

Fair Value

$101.60

Current Price

$224.47

$122.87 premium

UndervaluedFair: $101.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

NHC4 strengths · Avg: 9.5/10
EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.7010/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.828/10

Growing faster than its price suggests

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

NHC0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : NHC

The strongest argument for NHC centers on EPS Growth, Debt/Equity, Altman Z-Score. PEG of 0.82 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : NHC

No major red flags identified for NHC, but monitor valuation.

Key Dynamics to Monitor

NHC carries more volatility with a beta of 0.63 — expect wider price swings.

NHC is growing revenue faster at 8.8% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NHC scores higher overall (61/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

National HealthCare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

National HealthCare Corporation operates, manages, and provides services to skilled nursing facilities, assisted living facilities, independent living facilities, home health programs, and a behavioral health hospital. The company is headquartered in Murfreesboro, Tennessee.

Want to dig deeper into these stocks?